Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly [PDF]
, 2016 PURPOSE: Cushing’s disease (CD) and acromegaly are characterized by excessive hormone secretion resulting in comorbidities such as impaired glucose metabolism, diabetes and hypertension.
Silverstein, Julie M
core +2 more sources
Somatostatin agonist pasireotide inhibits exercise stimulated growth in the male Siberian hamster (Phodopus sungorus) [PDF]
, 2017 R.Dumbell was supported by a University of Aberdeen PhD studentship and a research visit grant awarded by the British Society of Neuroendocrinology. Further support was provided by the Scottish Government Rural and Environment Science and Analytical ...
Barrett, P +6 more
core +2 more sources
Time spent with cats is never wasted: Lessons learned from feline acromegalic cardiomyopathy, a naturally occurring animal model of the human disease [PDF]
, 2018 BackgroundIn humans, acromegaly due to a pituitary somatotrophic adenoma is a recognized cause of increased left ventricular (LV) mass. Acromegalic cardiomyopathy is incompletely understood, and represents a major cause of morbidity and mortality.
A Colao +80 more
core +2 more sources
Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly [PDF]
, 2017 The granulation pattern of somatotroph adenomas is well known to be associated with differing clinical and biochemical characteristics, and it has been shown that sparsely granulated tumours respond poorly to commonly used somatostatin receptor ligands ...
Bakhtiar +9 more
core +6 more sources
Diabetes mellitus remission in a cat with pituitary-dependent hyperadrenocorticism after trilostane treatment [PDF]
, 2018 An 8-year-old male neutered Persian cat was presented with polyuria, polydipsia, polyphagia and muscle weakness associated with a 7 month history of diabetes mellitus (DM).
Adriana Cunha Muschner +4 more
core +3 more sources
Pasireotide in the Personalized Treatment of Acromegaly
Frontiers in Endocrinology, 2021 The delay in controlling the disease in patients who do not respond to first-line treatment with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified in years, as every modification in the medical therapy requires some
Manel Puig-Domingo +13 more
doaj +1 more source
The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome [PDF]
, 2019 When hypertension, a pathology that is frequently found in the general population, presents in a young patient, secondary causes such as Cushing's syndrome (CS), a rare disease characterized by long-term elevated cortisol levels, should be considered ...
Barbot, Mattia +2 more
core +1 more source
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial [PDF]
, 2014 International audiencePurpose Report the efficacy and safety of pasireotide sc in patients with Cushing's disease during an open-ended, open-label extension to a randomized, double-blind, 12-month, Phase III study.
Boscaro, Marco +10 more
core +4 more sources
Frontiers in Endocrinology, 2019 Introduction: The efficacy and safety of subcutaneous (sc) pasireotide have been evaluated in a Phase III trial. Here, we report safety and efficacy results from a multinational, expanded-access study of pasireotide sc in patients with Cushing's disease (
Maria Fleseriu +6 more
doaj +1 more source
Complications of Cushing's syndrome: state of the art [PDF]
, 2016 Cushing's syndrome is a serious endocrine disease caused by chronic, autonomous, and excessive secretion of cortisol. The syndrome is associated with increased mortality and impaired quality of life because of the occurrence of comorbidities.
Biller, Beverly M. K +5 more
core +1 more source